Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()

Antiangiogenic therapy has shown promising results in preclinical and clinical trials. However, tumor cells acquire resistance to this therapy by gaining ability to survive and proliferate under hypoxia induced by antiangiogenic therapy. Combining antiangiogenic therapy with hypoxia-activated prodru...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Transl Oncol
Main Authors: Kumar, Sushil, Sun, Jessica D., Zhang, Libo, Mokhtari, Reza Bayat, Wu, Bing, Meng, Fanying, Liu, Qian, Bhupathi, Deepthi, Wang, Yan, Yeger, Herman, Hart, Charles, Baruchel, Sylvain
Formato: Artigo
Idioma:Inglês
Publicado: Neoplasia Press 2018
Assuntos:
Original article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6041570/
https://ncbi.nlm.nih.gov/pubmed/29803017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2018.05.004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares